European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - If approved, avelumab, an investigational anti-PD-L1 IgG1, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma - The Marketing Authorization Application is based on Phase II data from the ...